Molecular structure of zanamivir
Find information on thousands of medical conditions and prescription drugs.

Zanamivir

Zanamivir is a neuraminidase inhibitor used in the treatment of and prophylaxis of both influenza A and influenza B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza®. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Development

Zanamivir was discovered in 1989 by scientists at the Australian biotechnology company Biota Holdings, working in conjunction with the CSIRO and the Victorian College of Pharmacy. The development was part of Biota's ongoing program to develop antiviral agents through rational drug design. An outline of the successful rational design strategy used was published in a paper in Nature (von Itzstein et al., 1993).

The strategy relied on the availability of the crystal structure of influenza neuraminidase which was achieved by x-ray crystallography. It was known as far back as 1974 that 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA), a sialic acid analogue, was an inhibitor of neuraminidase (Meindl et al., 1974). Using the crystal structure of neuraminidase and DANA as a starting point, the researchers employed a computer-aided process to attempt to design a molecule which better fitted (and therefore inhibited) the active site of neuraminidase. Zanamivir, a transition-state analogue inhibitor of neuraminidase, was the result.

In 1990, zanamivir was licensed to Glaxo (now GlaxoSmithKline) for exclusive worldwide development and marketing. In 1999, the product was approved for marketing in the US and subsequently has been registered by GSK in a total of 70 countries.

Limitations

Whilst zanamivir proved to be a potent and effective inhibitor of influenza neuraminidase and inhibitor of influenza virus replication in vitro and in vivo, this didn't necessarily translate into a successful clinical treatment for influenza. In clinical trials it was found that zanamivir was able to reduce the time to symptom resolution by 1.5 days provided therapy was started within 48 hours of the onset of symptoms.

A further limitation concerns the poor oral bioavailability of zanamivir. This meant that oral dosing was impossible limiting dosing to the parenteral routes. Zanamivir, therefore, is administered by inhalation - a route that was chosen for patient compliance with therapy. But even this route of administration is not acceptable to many in the community.

A troubled commercial venture

Biota, being only a small company, was not able to bring the drug to market by itself. Consequently, it was licensed to Glaxo (now GlaxoSmithKline) to complete development and to market internationally as Relenza, delivered via Glaxo's proprietary, and some would say cumbersome, Diskhaler inhalation device. The license agreement entitled Biota to receive a 7% royalty on Glaxo's sales of Relenza.

A combination of factors has resulted in the limited commercial success of zanamivir (Relenza). The relatively small effect on the timecourse of influenza symptoms, the inhalation dosage form, a less-than-ideal device, and high expense make it a difficult product to market well. And although zanamivir was the first neuraminidase inhibitor to the market, it had only a few months lead over the second entrant, oseltamivir (Tamiflu), with an oral formulation much preferred by patients. Faced with this competition, GSK effectively abandoned the product.

Read more at Wikipedia.org


[List your site here Free!]


Effect Of Patient Education And Zanamivir On Morbidity Of Influenza In A Private Practice - Abstract
From CHEST, 10/1/00 by Richard S Castaldo

Richard S Castaldo, MD(*); Anthony Mato, BS; Cheryl A Stoukides, PharmD and Alan F Kaul, MS, MBA. Buffalo Managed Care, Buffalo, NY and Medical Outcomes Management, Foxborough, MA.

PURPOSE: To evaluate the effect of patient education, the use of ancillary services, and the development of complications in patients infected with influenza virus and to compare outcomes between zanamivir treated and untreated patients.

METHODS: This open-label study evaluated all high-risk patients seen in a private-practice influenza education clinic who later presented with influenza (Group I) and all patients initially presenting with influenza (Group II). Group I received education on how to recognize common symptoms, instructions to call the office [is less than or equal to] 48 hours of experiencing [is greater than or equal to] 2 symptoms, and a zanamivir prescription that they were advised to hold. Patients in Group II were given a zanamivir prescription upon being diagnosed with influenza with an onset [is less than or equal to] 48 hours. Patients between groups and within each group were compared for age, gender, race, education, co-morbidities, zanamivir and antibiotic use, and use of ancillary services. Therapy was evaluated within each group based upon duration of illness and ancillary service use.

RESULTS: Of the initial 763 patients identified for possible inclusion in the study, 53 became sick and were analyzed. Group I vs Group II: Compared to Group II, patients in Group I were more likely to be diabetic (9/28 vs 2/25, p=0.043), have a cardiac history (23/28 vs 12/25, p=0.009), and have a greater mean number of chronic conditions (1.5 vs 0.84, p=0.0158). Group I: 28 patients (mean age = 64.1 years) were evaluated. No differences were noted between the 25 zanamivir treated and the 3 untreated patients in any baseline data. Untreated patients were more likely to receive antibiotic therapy (p=0.045). The duration of illness was less in zanamivir-treated (4.8 [+ or -] 1.5) days than in untreated (11.7 [+ or -] 5.0, p=0.006) patients. No differences were noted in using ancillary services.

Group II: 25 patients (mean age = 57.4 years) were evaluated. No differences were noted between the 21 zanamivir treated and the 4 untreated patients in any baseline data, co-morbidities, chronic conditions, use of ancillary services, or duration of illness.

CONCLUSION: In this pilot study, high-risk patients participating in an educational program for early detection and treatment of influenza with zanamivir had a shorter duration of illness than untreated patients. In those patients who did not participate in the educational program, no differences were noted in any observed parameters. A larger-scale study may be warranted to confirm these findings.

CLINICAL IMPLICATIONS: Influenza education particularly in high-risk patients leading to potentially earlier diagnosis and treatment with zanamivir may shorten the duration of illness and lessen morbidity in those patients subsequently infected.

GRANT SUPPORT: An unrestricted educational grant from Glaxo Wellcome.

COPYRIGHT 2000 American College of Chest Physicians
COPYRIGHT 2001 Gale Group

Return to Zanamivir
Home Contact Resources Exchange Links ebay